Open AccessP68 ‐ Immunogenicity of 13‐valent conjugate pneumococcal vaccine (PCV13) in children with asthma or recurrent wheeze receiving inhaled corticosteroids (ICS)
Author(s) -
Giannopoulou Lefki,
PanaghiotopoulouGartagani Polytimi,
Kyritsi Eleni,
Kaditis Athanasios,
Theodoridou Maria,
Spoulou Vasiliki
Publication year - 2014
Publication title -
clinical and translational allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.979
H-Index - 37
ISSN - 2045-7022
DOI - 10.1186/2045-7022-4-s1-p123
Subject(s) - medicine , wheeze , vaccination , asthma , immunogenicity , pneumococcal conjugate vaccine , streptococcus pneumoniae , immunology , allergy , pediatrics , antibody , antibiotics , microbiology and biotechnology , biology
Patients with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). Therefore, routine vaccination against Streptococcus Pneumoniae is suggested for all children suffering from asthma or recurrent wheeze. Inhaled corticosteroids (ICS) are the preferred treatment for initiating long-term control therapy in these children. Their effect on the immunogenicity of PCV13 is yet unknown.